We recently reported endoplasmic reticulum translocon complex protein SSR3 as a predictive biomarker for glioma and breast cancer susceptibility to this drug.22 In a companion manuscript (Dmello et al., submitted to Neuro-Oncology Advances), we report an analysis of available tumor samples from this phase II trial (NCT01967810), where we evaluated the correlation with baseline SSR3 expression with OS on this cohort. This evidence concerns the gene SSR3 and neoplasm.